UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill
AstraZeneca is making a big push into the weight-loss drug market, striking an exclusive licence agreement with a Chinese company for an obesity and type 2 diabetes pill that is in early stage development.
Britain’s biggest drugmaker said it had agreed a deal with Eccogene, based in Shanghai, for an experimental drug named ECC5004 that would also treat other cardiometabolic conditions such as heart disease and stroke. Eccogene will receive up to $2bn under the terms of the deal.
About Author
More Stories
Canadian company in negotiations with Trump to mine seabed
Hyundai facing legal action over car that can be stolen ‘effortlessly in seconds’
Australian house prices hit new peak as rate cut drives buyer demand